
Sign up to save your podcasts
Or


Expert insights on the latest clinical findings on targeting Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (Bcl-2) to treat B-cell malignancies.
Credit available for this activity expires: 1/12/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999658?ecd=bdc_podcast_libsyn_mscpedu
By Medscape4.3
2525 ratings
Expert insights on the latest clinical findings on targeting Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (Bcl-2) to treat B-cell malignancies.
Credit available for this activity expires: 1/12/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999658?ecd=bdc_podcast_libsyn_mscpedu

135 Listeners

696 Listeners

495 Listeners

170 Listeners

101 Listeners

886 Listeners

13 Listeners

17 Listeners

291 Listeners

262 Listeners

3,331 Listeners

1,152 Listeners

196 Listeners

89 Listeners

513 Listeners

363 Listeners

171 Listeners

61 Listeners

8 Listeners

430 Listeners